Banyu’s Drug Ingredient Taken Off Anti-Doping List
This article was originally published in PharmAsia News
Executive Summary
Banyu announced Jan. 8 that androgenetic alopecia drug Propecia (finasteride) has been taken off the World Anti-Doping Agency's doping material list. In 2007, Softbank Hawks baseball player Rick Guttormson, who was using the drug to treat AGA, was barred from playing for 20 days and fined ¥7.5 million. WADA's decision to amend the list and take finasteride off is based on new analyzing technology that allows the agency to differentiate barred material from finasteride. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.